Champalimaud Foundation

What Champalimaud Foundation does

Champalimaud Foundation (legal name: The D. Anna de Sommer Champalimaud and Dr. Carlos Montez Champalimaud Foundation) is a Lisbon-headquartered Portuguese non-profit foundation established through the will of António de Sommer Champalimaud (1918-2004) and operational since 2007. It operates an integrated biomedical model centred on its proprietary "Fusion Research" methodology, which deliberately bridges laboratory science and clinical application through research-based clinics and clinically-based research. The Foundation serves three primary constituencies: patients seeking advanced oncology, neurological, and diagnostic care; international research scientists and PhD students pursuing fundamental and translational work in neuroscience and cancer; and the global vision science and blindness-prevention community via the €1,000,000 António Champalimaud Vision Award.

The Foundation's core offerings span two integrated pillars. Champalimaud Research conducts world-leading neuroscience, physiology and cancer programmes across three formal programmes (Champalimaud Neuroscience Programme, Physiology and Cancer Programme, and Experimental Clinical Research Programme), supported by scientific platforms including the BioSpec 18 Tesla preclinical MRI (world's highest-field horizontal-bore system, commissioned May 2026 with Bruker Corporation), Advanced BioImaging and BioOptics, Flow Cytometry, Animal Models, Molecular and Transgenic Tools, and a Hardware and Software Platform. Champalimaud Clinical Centre delivers translational interdisciplinary care including oncology, radiotherapy, immunotherapy (notably NK cell immunotherapy for pancreatic cancer), precision surgery (TME), and diagnostic imaging (MRI, PET, CT, ultrasound, mammography). Specialised sub-brands include the Botton-Champalimaud Pancreatic Cancer Centre, the Centre for Restorative Neurotechnology (comprising the Digital Neurotherapeutics Centre, Neuroscience of Disease Programme, and Neurotechnology Warehouse) which deploys AI-driven VR/AR and neuromodulation for brain disorders, and C-TRACER in India for translational eye research.

The Foundation's business model is a hybrid of endowment-funded operations, clinical services revenue, competitive research grants (notably European Research Council and FCT), education programme revenue (INDP, ICDP PhD programmes; CAJAL Advanced Neuroscience Training courses), and the Vision Award endowment. It reaches customers through direct clinical appointments (including an International Patient Office), global PhD and CAJAL programme applications, public science communication events (30+ events, 10,000+ attendees), the Champimóvel mobile science initiative (300,000+ children since 2008), and the Vision Award nomination cycle. Strategic partners include Bruker Corporation (technology), Würth Group (pancreatic cancer research), WHO and IAPB (Vision Award), and Bordeaux Neurocampus (CAJAL training).

Name

Champalimaud Foundation

Legal name

The D. Anna de Sommer Champalimaud and Dr. Carlos Montez Champalimaud Foundation

Website

https://fchampalimaud.org

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The Champalimaud Foundation is a Lisbon-based non-profit operating integrated biomedical research, translational clinical care in oncology and neuroscience, and PhD education, with specialized centres for pancreatic cancer and restorative neurotechnology and the world's largest €1M vision science award.

Ownership category

akta.pro rank

Product category

Biomedical Research and Clinical Care

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Health Services (8000)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Imaging Core Labs & Clinical Endpoint Adjudication (HLAGAEAH)

Keywords

• Biomedical research services
• Clinical oncology care
• Neuroscience research
• PhD doctoral programmes
• Vision science awards

Headquarters

HQ city

Lisbon

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Services Revenue: Revenue generated from the Champalimaud Clinical Centre providing medical consultations, diagnostic exams (MRI, PET, CT, ultrasound, mammography, etc.), and oncology treatments to patients
2. Research Grants and Funding: Funding from European Research Council (€728 million in grants to Portugal with major projects), national research funding (FCT), and international partnerships supporting research programmes
3. Vision Award Endowment: The €1,000,000 annual Vision Award is funded through the Foundation's endowment, established by founder António de Sommer Champalimaud. The endowment also supports all Foundation operations including research and clinical care.
4. Education Programmes: Revenue from PhD programmes (INDP and ICDP), CAJAL training courses, and educational outreach activities including Champimóvel

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

The Champalimaud Foundation is a non-profit biomedical institution that integrates advanced research with translational clinical care. Through its Champalimaud Clinical Centre it provides oncology, neurology, and advanced diagnostic imaging services to patients, while Champalimaud Research conducts fundamental and translational research in neuroscience and cancer. It also operates PhD programmes (INDP, ICDP), the CAJAL Advanced Neuroscience Training Programme, and awards the world's largest annual vision science prize (€1,000,000 António Champalimaud Vision Award).

Product overview

The Champalimaud Foundation is a biomedical research and clinical care institution organized as a unified platform integrating research and clinical operations. The core offerings consist of the Champalimaud Clinical Centre (providing translational interdisciplinary healthcare across oncology, neuroscience, and diagnostics) and Champalimaud Research (conducting world-leading fundamental and translational research in neuroscience, physiology, and cancer). Specialized sub-brands include the Botton-Champalimaud Pancreatic Cancer Centre, the Centre for Restorative Neurotechnology (comprising the Digital Neurotherapeutics Centre, Neuroscience of Disease Programme, and Neurotechnology Warehouse), and C-TRACER for eye research. Scientific and technological platforms support research with MRI, bioimaging, and hardware/software capabilities. Education programmes include PhD programmes in Neuroscience (INDP) and Cancer (ICDP), the CAJAL Advanced Neuroscience Training Programme, and the mobile Champimóvel educational experience. The António Champalimaud Vision Award (€1,000,000) recognizes advances in vision research or blindness prevention. Art-science initiatives include the Bridges to the Unknown programme and Ar Magazine science communication platform.

Differentiator

Problem solved

Functional benefit

Brands

• António Champalimaud Vision Award: A €1,000,000 annual award presented alternately for advances in vision research (even years) and contributions to fighting blindness in developing regions (odd years).
• Champimóvel
• Botton-Champalimaud Pancreatic Cancer Centre
• Centre for Restorative Neurotechnology
• Digital Neurotherapeutics Centre
• Champalimaud PhD Programmes
• CAJAL Advanced Neuroscience Training Programme
• Ar Events

Products and services

• Champalimaud Clinical Centre A translational, interdisciplinary clinical care facility providing medical services across multiple specialties including oncology, neuroscience, and diagnostic imaging (MRI, PET, CT, ultrasound, mammography, bone densitometry) for patients at the Lisbon facility. Includes an International Patient Office for global patients.
• Champalimaud Research World-leading fundamental and translational research division focused on neuroscience, physiology, and cancer, hosting the Champalimaud Neuroscience Programme, Champalimaud Physiology and Cancer Programme, and Champalimaud Experimental Clinical Research Programme.
• Botton-Champalimaud Pancreatic Cancer Centre A specialized centre dedicated to pancreatic cancer research and treatment, hosting the annual Botton-Champalimaud International Pancreatic Cancer Conference.
• Digital Neurotherapeutics Centre (DNTx) Clinical centre within the Centre for Restorative Neurotechnology combining neuromodulation, digital tools, VR/AR immersive environments with medication, psychotherapy, and rehabilitation for brain disorders including depression, OCD, Alzheimer's, Parkinson's, and stroke.
• Centre for Restorative Neurotechnology Division comprising the Digital Neurotherapeutics Centre, Neuroscience of Disease Programme, and Neurotechnology Warehouse focused on developing neurotechnologies for brain repair and rehabilitation.
• António Champalimaud Vision Award Annual €1,000,000 award alternating between advances in vision research/restoration (even years) and contributions to fighting blindness in developing regions (odd years). The world's largest award in vision science and blindness prevention.
• International Neuroscience Doctoral Programme (INDP) International PhD programme providing integrative, state-of-the-art education in neuroscience with 9-12 months of classes and lab rotations followed by doctoral research.
• International Cancer Doctoral Programme (ICDP) International PhD programme providing integrative education in cancer research, covering molecular, cellular, and clinical basis of cancer within the broader context of the organism.
• CAJAL Advanced Neuroscience Training Programme Four annual neuroscience training courses held at Champalimaud Centre for the Unknown in Lisbon and Bordeaux Neurocampus, providing advanced neuroscience training for researchers worldwide.
• Experimental Magnetic Resonance Imaging (MRI) Platform Scientific platform providing MRI capabilities including the BioSpec 18 Tesla preclinical MRI system for advanced neuroscience and cancer research imaging. Supports internal research groups and clinical areas.
• Advanced BioImaging and BioOptics Experimental Platform Scientific platform providing advanced bioimaging and optical imaging technologies for research groups and clinical areas.
• Hardware and Software Platform Scientific platform developing custom hardware and software solutions for research, including scientific instrumentation and computational tools.
• C-TRACER (Champalimaud Translational Centre for Eye Research) Translational eye research programme launched in India in 2008 supporting cutting-edge vision research and bringing breakthroughs from laboratory to clinic.
• Bridges to the Unknown — Crossing Art with Science Art-science initiative bridging scientific research and artistic creation through residencies, exhibitions, performances, and public events.
• Champimóvel Mobile Science Education Mobile 3D interactive experience traveling to schools across Portugal and Spain since 2008, introducing children to medical science concepts through a simulator, 3D video, and educational games.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability12 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core, flagship and major.

• Bruker CorporationcoreTechnology or Integration · 26 May 2026Bruker Corporation commissioned the BioSpec 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon. The system supports advanced cancer and neuroscience research with increased spatial resolution and sensitivity for magnetic resonance imaging and spectroscopic imaging methods.
• World Health Organisation (WHO)flagshipStrategic or Co-development PartnerThe António Champalimaud Vision Award was launched during the 'Vision 2020 - The Right to Sight' global initiative for blindness prevention in collaboration with WHO and the International Agency for the Prevention of Blindness (IAPB).
• International Agency for the Prevention of Blindness (IAPB)flagshipStrategic or Co-development PartnerIAPB co-founded the Vision 2020 initiative with WHO and partners with the Foundation for the annual Vision Award programme. IAPB was a 2025 Vision Award laureate recognized alongside LCIF and The Fred Hollows Foundation.
• Bordeaux NeurocampuscoreStrategic or Co-development PartnerBordeaux Neurocampus hosts 2 of the 4 yearly CAJAL Advanced Neuroscience Training Programme courses, partnering with Champalimaud Centre for the Unknown in Lisbon to establish recurring neuroscience training in Europe.
• Würth GroupmajorStrategic or Co-development PartnerThe Würth Group representatives visited the Champalimaud Foundation for a follow-up on the Pancreatic Cancer Research Programme, indicating an ongoing research partnership in cancer research.
• C-TRACER India Programme PartnerscoreStrategic or Co-development PartnerChampalimaud Translational Centre for Eye Research (C-TRACER) launched in India in 2008 to support cutting-edge vision research, reflecting the Foundation's belief in translational science bringing breakthroughs from laboratory to clinic worldwide.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Cold Spring Harbor Laboratory: Private non-profit research and education institution focused on cancer and neuroscience. Comparable to Champalimaud in private non-profit research operations, advanced training programmes, and disease-focused research scope.
• Institut Curie: France-based private foundation operating a research centre and hospital focused on cancer research and treatment. Closely comparable to Champalimaud's integrated research-clinical oncology model and non-profit foundation status.
• Salk Institute for Biological Studies: Independent non-profit research institute focused on neuroscience, cancer and plant biology. Comparable to Champalimaud Research as a non-profit research foundation with multi-disciplinary life science programmes and global scientific prestige.
• Francis Crick Institute: London-based biomedical discovery institute conducting fundamental research with translational aims. Comparable to Champalimaud Research in non-profit biomedical research operations and international scientific collaboration.
• Allen Institute: Philanthropically funded biomedical research organisation focused on neuroscience and brain science. Closely comparable to Champalimaud Research in mission scope, neuroscience focus, and private foundation funding model.
• Gladstone Institutes: San Francisco-based non-profit biomedical research organisation affiliated with UCSF, focused on neurological disease, cancer and cardiovascular research. Comparable in non-profit research foundation model and translational mission.

Broad incumbents

• Karolinska Institutet: Swedish medical university integrating biomedical research with clinical training and patient care. Comparable to Champalimaud's integrated research-clinical model and doctoral training programmes (INDP/ICDP).
• Max Planck Institutes: Germany-based network of non-profit research institutes conducting fundamental research in life sciences, neuroscience and related fields. Comparable in scale of research operations and doctoral training.
• Howard Hughes Medical Institute: A large US biomedical research philanthropy supporting investigator-driven research and clinical translation. Comparable to Champalimaud as a privately endowed biomedical research foundation with strong brand and capital base.
• Wellcome Trust: UK-based global charitable foundation funding biomedical research and public health. Comparable to Champalimaud in endowment-driven funding of biomedical research, clinical translation, and global health initiatives.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCjZ337tYdjkl974tQsNdwCQ
• Facebookfacebook.com/ChampalimaudFoundation
• LinkedInlinkedin.com/company/champalimaud-foundation
• Instagraminstagram.com/champalimaudfoundation
• Xx.com/champalimaudf

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Champalimaud Foundation